Controlled release of doxorubicin
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Apr 9, 2002
Grant Date -
N/A
app pub date -
Oct 3, 2000
filing date -
Oct 19, 1999
priority date (Note) -
Expired
status (Latency Note)
Importance
Abstract
A controlled release doxorubicin containing composition comprises doxorubicin physically entrapped in a dextran-methacrylate biodegradable hydrogel. The composition provides a rapid initial release of doxorubicin over a period of 5 to 7 hours followed by slow release. Increased degree of substitution in the dextran methacrylate decreases cumulative doxorubicin release. The composition provides higher cumulative release in acid pH (e.g., the stomach) than at physiological pH at lower degrees of substitution. The composition allows administration alternatives to the bolus intravenous and continuous intravenous methods of administration now used for doxorubicin. The composition can be prepared without the use of heat (which can result in heat destruction of doxorubicin) and is prepared without chemical cross-linker such as glutaraldehyde and the toxicity associated therewith.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully